Healthcare Glenmark launches Favipiravir for treatment of mild to moderate COVID-19 patients Updated : June 22, 2020 09:47 AM IST Glenmark’s Fabiflu is the first oral Favipiravir-approved medication for the treatment of COVID-19 and has been launched in few centers. Fabiflu, available as a 200 mg tablet, has been priced at Rs 103 per tablet. Favipiravir is also approved for compassionate use in Japan and nearly 2,050 patients have already been administered Favipiravir. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.